Lexeo Therapeutics, Inc. Common Stock

LXEONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
4.75 USD
↗ 0.05 (1.06%)AT CLOSE (11:59 AM EDT)
4.77
↗ 0.02 (0.32%)
POST MARKET (AS OF 04:32 PM EDT)
Post Market
AS OF 04:32 PM EDT
4.77
↗ 0.02 (0.32%)
🔴Market: CLOSED

Lexeo Therapeutics, Inc. Common Stock (LXEO) trades at $4.75 per share. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest LXEO is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jun 26, 2026.

Open?$4.69
High?$4.92
Low?$4.67
Prev. Close?$4.70
Volume?2.3M
Avg. Volume?890.5K
VWAP?$4.75
Rel. Volume?2.63x
Bid / Ask
Bid?$3.78 × 100
Ask?$5.70 × 100
Spread?$1.92
Midpoint?$4.74
Valuation & Ratios
Market Cap?373.0M
Shares Out?78.5M
Float?76.6M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?1.61
EPS?-$1.11
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
59
Market Cap
369.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lexeotx.com
Listed
2023-11-03
Address
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
Phone: (212) 547-9879
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
77
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?9.23Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?18.38%High
Short Interest?14.1M
Days to Cover?18.8
Free Float76.6M
Avg Daily Volume748.9K
Settlement Date2026-06-15
Financial Health
Current Ratio?14.16Strong
Quick Ratio?14.16Strong
Cash Ratio?5.06Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
84
1.61CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.1CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-37.8%WEAK▾
ROA?
S&P
3
-34.9%WEAK▾
Cash Flow & Enterprise
FCF?$-98421000
Enterprise Value?$301.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist